Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Universe PharmaceuticalsUPC -7.14%62 EV-to-EBITDA is 7.30 as of Jul. 17, 2026, which is 421% above its 10-year median of 1.40. GuruFocus rates UPC with a GF Score™ of 62/100 and a GF Value™ of $5.18 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 741 Drug Manufacturers companies, Universe Pharmaceuticals ranks better than 75.71% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Universe Pharmaceuticals's enterprise value is $-21.32 Mil.
Universe Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Sep. 2025 was $-2.92 Mil. Therefore, Universe Pharmaceuticals's EV-to-EBITDA for today is 7.30.
The historical rank and industry rank for Universe Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
UPC'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -3.86 Med: 1.4 Max: 9.97
Current: 7.3
During the past 8 years, the highest EV-to-EBITDA of Universe Pharmaceuticals was 9.97. The lowest was -3.86. And the median was 1.40.
UPC's EV-to-EBITDA is ranked better than 75.71% of 741
companies
in the Drug Manufacturers industry
Industry Median: 13.03
vs UPC: 7.30
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Universe Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Universe Pharmaceuticals's share price for today is $4.65.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Universe Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2025 was $-8.060.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Universe Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Universe Pharmaceuticals EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Universe Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Universe Pharmaceuticals's EV-to-EBITDA falls into.
Universe Pharmaceuticals's current Enterprise Value is $-21.32 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Universe Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Sep. 2025 was $-2.92 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Universe Pharmaceuticals (UPC) has a EV-to-EBITDA of 7.30 as of Jul. 17, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Universe Pharmaceuticals. This is 421% above median its historical median of 1.40. According to the industry distribution chart, Universe Pharmaceuticals ranks #180 out of 741 companies in the Drug Manufacturers industry, placing it in the top 24.3%.
Is Universe Pharmaceuticals' EV-to-EBITDA too high?
Universe Pharmaceuticals' current EV-to-EBITDA of 7.30 is 421% above median its 10-year median of 1.40. The Drug Manufacturers industry median EV-to-EBITDA is 13.03. Universe Pharmaceuticals' value of 7.30 is 44% below this industry median. Based on the distribution chart, Universe Pharmaceuticals ranks #180 out of 741 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Universe Pharmaceuticals has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Universe Pharmaceuticals' EV-to-EBITDA compare to CPMD and SHPH?
According to the Drug Manufacturers industry distribution chart, Universe Pharmaceuticals ranks #180 out of 741 companies for EV-to-EBITDA. This places Universe Pharmaceuticals in the top 24% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.03. Universe Pharmaceuticals' value of 7.30 is 44% below this benchmark. While the company's 10-year median is 1.40 vs. the industry median of 13.03, Universe Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.03, based on 741 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Universe Pharmaceuticals's current EV-to-EBITDA of 7.30 is 44% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Universe Pharmaceuticals. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Universe Pharmaceuticals's current EV-to-EBITDA is 7.30, which is 421% above median its own 10-year median of 1.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Universe Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Universe Pharmaceuticals (UPC) is currently considered Modestly Undervalued. The stock's GF Value™ is $5.18, compared to a current price of $4.65 — trading 10.2% below its estimated fair value. The current EV-to-EBITDA is 7.30, which is 421% above median its 10-year median of 1.40 and 44% below the Drug Manufacturers industry median of 13.03. Universe Pharmaceuticals' overall GF Score™ is 62/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Universe Pharmaceuticals (UPC), the current EV-to-EBITDA is 7.30 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Universe Pharmaceuticals (UPC) Overvalued in 2026?
Based on GuruFocus' analysis, Universe Pharmaceuticals stock appears to be undervalued.
The current stock price of $4.65 is trading 10.2% below its estimated GF Value™ of $5.18.
GuruFocus considers Universe Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for UPC:
EV-to-EBITDA: 7.30 (421% above median its 10-year median of 1.40)
GF Value™: $5.18 vs. price of $4.65 (10.2% below fair value)
Industry Position: 44% below the Drug Manufacturers median (#180 of 741)
No single metric tells the full story. See the UPC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Universe Pharmaceuticals Inc is a pharmaceutical company specializing in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions in the ageing process and promoting their general well-being. The company also sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. Its products are under two categories namely treatment and relief for common chronic health conditions in the elderly designed to achieve physical wellness and longevity (Chronic Condition Treatments), and cold and flu medications.
62GF Score
Get the complete analysis for UPC
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
UPC has been successfully added to your 
